Literature DB >> 6804746

Growth hormone in the regulation of hyperlipidemia.

P R Blackett, P K Weech, W J McConathy, J D Fesmire.   

Abstract

Plasma concentrations of triglyceride, cholesterol, and apolipoproteins A-I and B in young growth hormone deficient subjects were measured at intervals during the five weeks after initial hormone-replacement therapy. The mean concentrations of cholesterol, apolipoproteins A-I and B decreased significantly during that period: the decreases were progressive and in similar proportion to each other. Also, the amount by which apolipoprotein A-I concentration decreased was correlated with its plasmas concentration before treatment. The data suggests that growth hormone may play a role in the regulation of these three major plasma lipoprotein components and tend to suppress the development of hypercholesterolemia which has been observed in some adult growth hormone deficient subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804746     DOI: 10.1016/0026-0495(82)90121-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity.

Authors:  Diana Cruz-Topete; Britt Christensen; Lucila Sackmann-Sala; Shigeru Okada; Jens Otto L Jorgensen; John J Kopchick
Journal:  Eur J Endocrinol       Date:  2010-11-08       Impact factor: 6.664

2.  Influence of different dietary proteins on plasma growth hormone in rats.

Authors:  M Pfeuffer; W Wuttke; C A Barth
Journal:  Z Ernahrungswiss       Date:  1988-12

3.  Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.

Authors:  R H Böger; C Skamira; S M Bode-Böger; G Brabant; A von zur Muhlen; J C Frolich
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

4.  Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients.

Authors:  Diana Cruz-Topete; Jens Otto L Jorgensen; Britt Christensen; Lucila Sackmann-Sala; Thomas Krusenstjerna-Hafstrøm; Adam Jara; Shigeru Okada; John J Kopchick
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

5.  Associations between body height, body composition and cholesterol levels in middle-aged men. the coronary risk factor study in southern Sweden (CRISS).

Authors:  K M Henriksson; U Lindblad; B Agren; P Nilsson-Ehle; L Råstam
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

6.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

7.  Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Authors:  Lucila Sackmann-Sala; Juan Ding; Lawrence A Frohman; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2009-04-21       Impact factor: 2.372

8.  Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality.

Authors:  M Shahi; S A Beshyah; D Hackett; P S Sharp; D G Johnston; R A Foale
Journal:  Br Heart J       Date:  1992-01

9.  Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression.

Authors:  M Rudling; B Angelin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Comparative effect of two doses of growth hormone for growth hormone deficiency. The Dutch Growth Hormone Working Group.

Authors:  S De Muinck Keizer-Schrama; B Rikken; A Hokken-Koelega; J M Wit; S Drop
Journal:  Arch Dis Child       Date:  1994-07       Impact factor: 3.791

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.